Tailored drug tests aim to extend life in aggressive brain cancer
NCT ID NCT06512311
First seen Apr 24, 2026 · Last updated Jun 13, 2026 · Updated 16 times
Summary
This study tests whether using a patient's own tumor cells to find the best drugs can improve survival in people with a newly diagnosed, aggressive brain cancer called glioblastoma. About 240 adults will either receive standard treatment or have their tumor cells tested in a lab to choose personalized medicines. The goal is to see if this tailored approach helps people live longer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AKH Vienna, Department for Internal Medicine I, Oncology
RECRUITINGVienna, State of Vienna, 1090, Austria
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.